Publications by authors named "Steven Cicero"
Article Synopsis
- A report studied how a special imaging test called 18 F-PBR06-PET can help find signs of brain cell problems in people with multiple sclerosis (MS).
- The study looked at 30 scans from 22 MS patients and compared their results with 8 healthy people to see how effective different treatments were.
- Results showed MS patients had higher brain activity scores than healthy people, and even though stronger treatments helped reduce this activity, it still wasn't completely normal, linking it to their symptoms and brain changes.
A 69-year-old woman with progressive short-term memory deficits was diagnosed with Alzheimer disease (MMSE 26/30, CDR 0.5) and underwent PET using 18 F-PBR06, a second-generation 18-kDa translocator protein ligand, targeting brain microglia and astrocytes. SUV and voxel-by-voxel binding potential maps (using simplified reference tissue method and a cerebellar pseudo-reference region) were generated.
View Article and Find Full Text PDFUtility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline.
Am J Alzheimers Dis Other Demen
March 2023
In older adults with cognitive decline and epilepsy, diagnosing the etiology of cognitive decline is challenging. We identified 6 subjects enrolled in the Imaging Dementia-Evidence of Amyloid Imaging Scanning (IDEAS) study and nonlesional epilepsy. Three cognitive neurologists reviewed each case to determine the likelihood of underlying Alzheimer's disease (AD) pathology.
View Article and Find Full Text PDFArticle Synopsis
- Multiple System Atrophy (MSA) is a deadly neurodegenerative disease linked to protein aggregation and shares similarities with Parkinson's disease; its complexity and fast progression make drug development challenging.
- Researchers have created a cohort of 69 carefully assessed MSA patients and are recruiting them into a unique clinical trial setup that tracks individual patient progress over time.
- The study includes extensive patient phenotyping, collection of biospecimens, and development of induced pluripotent stem cell (iPSC) models to enhance understanding of MSA and improve chances of successful therapies through personalized medicine.
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis.
Neurol Neuroimmunol Neuroinflamm
March 2022
Background And Objectives: This [F]fluorodeoxyglucose (FDG) PET study evaluates the accuracy of semiquantitative measurement of putaminal hypermetabolism in identifying anti-leucine-rich, glioma-inactivated-1 (LGI1) protein autoimmune encephalitis (AE). In addition, the extent of brain dysmetabolism, their association with clinical outcomes, and longitudinal metabolic changes after immunotherapy in LGI1-AE are examined.
Methods: FDG-PET scans from 49 age-matched and sex-matched subjects (13 in LGI1-AE group, 15 in non-LGI1-AE group, 11 with Alzheimer disease [AD], and 10 negative controls [NCs]) and follow-up scans from 8 patients with LGI1 AE on a median 6 months after immunotherapy were analyzed.
Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion.
Neurol Neuroimmunol Neuroinflamm
September 2021
A 64-year-old man with primary progressive multiple sclerosis (Expanded Disability Status Scale 3.5) underwent PET using 18F-PBR06, a second-generation 18-kDa translocator protein ligand targeting activated brain microglia and astrocytes. Voxel-by-voxel statistical comparison of patient's PET images (acquired 60-90 minutes postinjection) with a healthy control data set was performed to generate a 3-dimensional z-score map of increased radiotracer uptake, which showed widespread increased glial activation in normal-appearing cerebral white matter, white matter lesional and perilesional areas, brainstem and cerebellum.
View Article and Find Full Text PDFRegional microglial activation in the substantia nigra is linked with fatigue in MS.
Neurol Neuroimmunol Neuroinflamm
September 2020
Objective: The goal of our study is to assess the role of microglial activation in MS-associated fatigue (MSAF) using [F-18]PBR06-PET.
Methods: Fatigue severity was measured using the Modified Fatigue Impact Scale (MFIS) in 12 subjects with MS (7 relapsing-remitting and 5 secondary progressive) and 10 healthy control participants who underwent [F-18]PBR06-PET. The MFIS provides a total fatigue score as well as physical, cognitive, and psychosocial fatigue subscale scores.
Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study.
Neurol Neuroimmunol Neuroinflamm
September 2019
Objective: To determine the value of [F-18]PBR06-PET for assessment of microglial activation in the cerebral gray matter in patients with MS.
Methods: Twelve patients with MS (7 relapsing-remitting and 5 secondary progressive [SP]) and 5 healthy controls (HCs) had standardized uptake value (SUV) PET maps coregistered to 3T MRI and segmented into cortical and subcortical gray matter regions. SUV ratios (SUVRs) were global brain normalized.